In addition, it has been found that WNT5A is an emerging druggable GC signal mediator, through transcriptional regulation by HNF4α (Chang et al., 2016; Nam et al., 2014), while another study (Chang et al., 2016) indicated poor prognosis of WNT5A high-expressing patients, in particular, in Lauren-classified diffuse-type GC patients. Here, HNF4A is linked to gastric cancer.